VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Deep and durable responses with KTE-X19 at the one-year follow up of ZUMA-2

Frederick Locke, MD, Moffitt Cancer Center, Tampa, FL discusses the one-year follow-up results of KTE-X19 (brexucabtagene autoleucel) use in relapsed/refractory mantle cell lymphoma (MCL) in the Phase II ZUMA-2 trial (NCT02601313). 60 patients were treated with KTE-X19, an anti-CD19 CAR-T cell therapy, and followed up for a minimum of a year. Responses were deep and durable, with an overall response rate over 90% and almost half the participants with ongoing responses at data cutoff. Adverse effects were manageable, results in a promising benefit-risk profile. The results show that KTE-X19 in this patient population where curative options are lacking is of significant clinical benefit. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter